SGP (SpyGlass Pharma) WACC %:10.68% (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGP SpyGlass Pharma Inc SGP
12 GF Score
Price $25.07
View Full Analysis

What is SpyGlass Pharma WACC %?

SpyGlass Pharma SGP -0.59% 12 WACC % is 10.68% as of Aug. 11, 2026. GuruFocus rates SGP with a GF Score™ of 12/100. Among 1,417 Biotechnology companies, SpyGlass Pharma ranks worse than 58.36% on this metric.

As of today (2026-08-11), SpyGlass Pharma's weighted average cost of capital is 10.68%%. SpyGlass Pharma's ROIC % is -260.74% (calculated using TTM income statement data). SpyGlass Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


SpyGlass Pharma  (NAS:SGP) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, SpyGlass Pharma's weighted average cost of capital is 10.68%%. SpyGlass Pharma's ROIC % is -260.74% (calculated using TTM income statement data). SpyGlass Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

SpyGlass Pharma WACC % Historical Data

* Premium members only.

The historical data trend for SpyGlass Pharma's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SpyGlass Pharma WACC % Chart

SpyGlass Pharma Annual Data
Trend Dec23 Dec24 Dec25
WACC %
0.00 0.00 0.00

SpyGlass Pharma Quarterly Data
Dec23 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
WACC % Get a 7-Day Free Trial 0.00 0.00 0.00 10.27 0.00

SGP vs RIGL, NGNE, OCS: WACC % Comparison

For the Biotechnology subindustry, SpyGlass Pharma's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SpyGlass Pharma WACC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SpyGlass Pharma's WACC % distribution charts can be found below:

* The bar in red indicates where SpyGlass Pharma's WACC % falls into.


SGP
12GF Score
SpyGlass Pharma Inc SGP
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SpyGlass Pharma WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, SpyGlass Pharma's market capitalization (E) is $838.541 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Jun. 2026, SpyGlass Pharma's latest one-year quarterly average Book Value of Debt (D) is $2.0973 Mil.
a) weight of equity = E / (E + D) = 838.541 / (838.541 + 2.0973) = 0.9975
b) weight of debt = D / (E + D) = 2.0973 / (838.541 + 2.0973) = 0.0025

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.705%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. SpyGlass Pharma's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.705% + 1 * 6% = 10.705%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Jun. 2026, SpyGlass Pharma's interest expense (positive number) was $-0 Mil. Its total Book Value of Debt (D) is $2.0973 Mil.
Cost of Debt = -0 / 2.0973 = 0%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -56.053 = 0%.

SpyGlass Pharma's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.9975*10.705%+0.0025*0%*(1 - 0%)
=10.68%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 10.68% mean?
SpyGlass Pharma (SGP) has a WACC % of 10.68% as of Aug. 11, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on SpyGlass Pharma and its competitors. According to the industry distribution chart, SpyGlass Pharma ranks #827 out of 1417 companies in the Biotechnology industry, placing it in the top 58.4%.
Is SpyGlass Pharma's WACC % too high?
SpyGlass Pharma's current WACC % is 10.68%. The Biotechnology industry median WACC % is 10.08. SpyGlass Pharma's value of 10.68% is 6% above this industry median. Based on the distribution chart, SpyGlass Pharma ranks #827 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's WACC % compare to RIGL and NGNE?
According to the Biotechnology industry distribution chart, SpyGlass Pharma ranks #827 out of 1417 companies for WACC %. This places SpyGlass Pharma in the lower half of its industry. The industry median WACC % is 10.08. SpyGlass Pharma's value of 10.68% is 6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.08, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SpyGlass Pharma's current WACC % of 10.68% is 6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on SpyGlass Pharma and its competitors. For the Biotechnology industry, the median WACC % is 10.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SpyGlass Pharma's current WACC % is 10.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current WACC % of 10.68%. The current WACC % is 10.68% and 6% above the Biotechnology industry median of 10.08. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current WACC % is 10.68% as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SpyGlass Pharma Business Description

Address 27061 Aliso Creek Road, Suite 100, Aliso Viejo, CA, USA, 92656
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score

Get the complete analysis for SGP

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.07
Price